Media

Streetwise Live! – Algernon Pharmaceuticals CEO Christopher Moreau and Dr. David Nutt Discuss Phase 1 DMT Study For Stroke
Proactive Investors Interview – Algernon Pharmaceuticals Phase 2 Human Study of Ifenprodil for IPF and Chronic Cough is Now 70% Enrolled
Stockhouse – Algernon Pharmaceuticals Makes Major Headway Toward Clinical Trials for Treatment of Stroke
Share via
Copy link
Powered by Social Snap